30th Jun 2022 13:29
30 June 2022
Diurnal Group plc
("Diurnal" or the "Company")
Block Listing Six Monthly Return
Pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies, Diurnal Group plc makes the following update on its block listing:
Name of applicant: | Diurnal Group plc | |||
Name of scheme: | Long Term Incentive Plan | |||
Period of return: | From: | 17 December 2021 | To: | 30 June 2022 |
Balance of unallotted securities under scheme(s) from previous return: | 5,775,000 | |||
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 0 | |||
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 665,732 | |||
Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 5,109,268 | |||
Name of contact: | Mike Scott |
Telephone number of contact: | +44 (0)20 3727 1000 |
For further information, please visit www.diurnal.co.uk or contact: | ||
Diurnal Group plc | +44 (0)20 3727 1000 | |
Richard Bungay, Interim Chief Executive Officer | ||
Panmure Gordon (UK) Limited (Nominated Adviser and Joint Corporate Broker) | +44 (0)20 7886 2500 | |
Corporate Finance: Freddy Crossley, Emma Earl | ||
Corporate Broking: Rupert Dearden
| ||
Stifel Nicolaus Europe Limited (Joint Corporate Broker) | +44 (0) 20 7710 7600 | |
Healthcare Investment Banking: Nicholas Moore, Samira Essebiyea, William Palmer-Brown | ||
Corporate Broking: Nick Adams, Nick Harland | ||
FTI Consulting (Media and Investor Relations) | +44 (0)20 3727 1000 | |
Simon Conway | ||
Victoria Foster Mitchell | ||
Alex Davis | ||
Vane Percy & Roberts (Medical Communications) | +44 (0) 173 782 1890 | |
Simon Vane Percy |
Notes to Editors
About Diurnal Group plc
Diurnal Group plc is a European, UK-headquartered, specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism and hypothyroidism. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.
For further information about Diurnal, please visit www.diurnal.com
Related Shares:
DNL.L